What are the issues associated with developing gene therapies for rare disease and are the current development models working?

Samir Nuseibeh, Els Henckaerts

20 June 2024

Commentary

A new era in medicine: unraveling the evolution and future of gene therapy

M Tanaka-Wakefield, J Ark, Y Gambhir et al

25 October 2023

Commentary

Overcoming challenges to CAR-T cell therapies in India

A Uppal, R Chakrabarti, N Chirmule et al

08 March 2023

Commentary

COVID-19: how is the pandemic changing the vaccines space?

Nicholas Jackson

24 May 2022

Commentary

Immuno-oncology therapies: a looming mid-life crisis?

Hansoo Kim, Danny Liew, Stephen Goodall

15 March 2022

Commentary

Regenerative medicine: new paradigms

Janet Lynch Lambert

01 February 2022

Commentary

Advancing patient access to cell & gene therapies: partnerships, pilots, & psyche

Heather McDonald, PhD

01 February 2022

Commentary

Critical need for establishing value that justifies the current rising costs of cell and gene therapy

Richard T Maziarz, MD

09 July 2021

Commentary

Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Shyam Patel, Sohel Talib, Maria Millan

05 October 2020

Commentary

Joint collaborations and future perspectives for gene therapies.

M Dabbous, B Borissov, C Dussart et al

03 September 2020

Commentary

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Stefan Scheding, Heather Main, Pontus Blomberg

18 August 2020

Commentary

Challenges in the adoption of regenerative medicine therapies, meeting summary

M Chaddah, S McMahon, J Kusena et al

13 August 2020

Commentary

Clinical trials in the era of Covid-19: successes, failures & ongoing challenges

Sven Kili

04 August 2020

Commentary